|Articles|July 1, 1999

Evaluating the Health Benefits of Atypical Agents in the Treatment and Management of Psychoses
Volume 5
Issue 10 Suppl

Assessment of Quality-of-Life Outcomes in Schizophrenic Patients

Author(s)Anthony F. Lehman, MD, MSPH

Download PDF: Assessment of Quality-of-Life Outcomes in Schizophrenic Patients

Articles in this issue

about 27 years ago

Article

Participating Faculty

about 27 years ago

Article

Introduction

about 27 years ago

Article

The Impact of Schizophrenic Patient Functionality on Service Utilization and Cost

about 27 years ago

Article

Evaluation of Outcomes for Atypical Antipsychotic Therapy and Psychosocial Rehabilitation in a Community Mental Health Center

about 27 years ago

Article

Modeling of Annual Treatment Costs and Health Outcomes of Antipsychotic Agents for Schizophrenic Populations

about 27 years ago

Article

The Emerging Role of Psychiatric Pharmacists

about 27 years ago

Article

CME/CE Quiz

about 27 years ago

Article

Selected Abstracts

about 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Assessment of Quality-of-Life Outcomes in Schizophrenic Patients

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access